Biotech

Lexeo Therapeutics Inc. (NASDAQ:LXEO) stock rose Monday as the company announced a regulatory update regarding its pivotal SUNRISE-FA 2 trial for gene therapy candidate LX2006. LXEO Stock Jumps The gene therapy company finalized the protocol for its SUNRISE-FA 2 pivotal trial, which aims to...

Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program. The decline follows a recent update indicating that the planned Phase 2a human influenza challenge study for its lead compound, tivoxavir marboxil...

Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLDN6 x CD3 T-cell engaging bispecific antibody, showing early signs of efficacy and a favorable safety profile in patients with advanced, late-line platinum-resistant ovarian cancer. The data, based on...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema (HAE). HAE is a rare genetic disorder that causes recurrent and...

Medicare's upcoming weight-loss drug program could create major bottlenecks for doctors as millions of seniors seek access to popular GLP-1 treatments such as Wegovy and Zepbound. Clinicians are warning that the July rollout could become one of the biggest drug launches in recent years, potentially...

Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP). An interim analysis of 40 patients completing Part A showed a 75% confirmed responder...

Amgen Inc. (NASDAQ:AMGN) has formally requested a hearing to challenge the U.S. Food and Drug Administration‘s proposal to withdraw approval for Tavneos (avacopan). The company argues that the drug's benefits continue to outweigh its risks for patients with a rare autoimmune disease. The...

Ascendis Pharma A/S (NASDAQ:ASND) on Thursday reported five-year results from its Phase 2 PaTH Forward trial, showing that TransCon PTH (palopegteriparatide) delivered sustained efficacy and safety in adults with hypoparathyroidism. The stock rose in Friday trading following the announcement. The...

Silence Therapeutics Plc (NASDAQ:SLN) shares are up during Friday’s session. On Thursday, the company highlighted follow-up data from its Phase 1 SANRECO study of divesiran. SLN Stock Catalyst: SANRECO Phase 1 Follow-Up Data Recent analyses from the Phase 1 SANRECO study show potential...

MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism. Hypoparathyroidism is a rare condition in which the...

AbbVie Inc. (NYSE:ABBV) stock is up slightly on Friday on new data presented at the European Hematology Association (EHA) 2026 Congress. The company unveiled results from the Phase 3 CLL14 trial involving its venetoclax-based therapy for chronic lymphocytic leukemia (CLL). New Venetoclax Data At...

Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune system mistakenly attacks and destroys platelets. The data show a favorable safety...

Aditxt Inc. (NASDAQ:ADTX) shares surged 16.92% to $0.015 in after-hours trading Thursday, extending a 29.73% intraday gain. The stock closed the regular session at $0.013, according to Benzinga Pro data. What You Should Know The move came alongside a Securities and Exchange Commission filing...

On Thursday, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk A/S’ (NYSE:NVO) Wegovy pill, clearing the company's first daily oral weight-management treatment for adults with obesity or overweight conditions linked to weight-related health issues. The...

Takeda Pharmaceutical Company Limited (NYSE:TAK) on Thursday shared topline results for the Phase 3 comparing zasocitinib (TAK-279) to Bristol-Myers Squibb Co.’s (NYSE:BMY) Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis (PsO). Head-To-Head Trial Meets Endpoints...